Remdesivir in adults with severe COVID-19 : a randomised, double-blind, placebo-controlled, multicentre trial
Copyright © 2020 Elsevier Ltd. All rights reserved..
BACKGROUND: No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models.
METHODS: We did a randomised, double-blind, placebo-controlled, multicentre trial at ten hospitals in Hubei, China. Eligible patients were adults (aged ≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection, with an interval from symptom onset to enrolment of 12 days or less, oxygen saturation of 94% or less on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or less, and radiologically confirmed pneumonia. Patients were randomly assigned in a 2:1 ratio to intravenous remdesivir (200 mg on day 1 followed by 100 mg on days 2-10 in single daily infusions) or the same volume of placebo infusions for 10 days. Patients were permitted concomitant use of lopinavir-ritonavir, interferons, and corticosteroids. The primary endpoint was time to clinical improvement up to day 28, defined as the time (in days) from randomisation to the point of a decline of two levels on a six-point ordinal scale of clinical status (from 1=discharged to 6=death) or discharged alive from hospital, whichever came first. Primary analysis was done in the intention-to-treat (ITT) population and safety analysis was done in all patients who started their assigned treatment. This trial is registered with ClinicalTrials.gov, NCT04257656.
FINDINGS: Between Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to remdesivir and 79 to placebo); one patient in the placebo group who withdrew after randomisation was not included in the ITT population. Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1·23 [95% CI 0·87-1·75]). Although not statistically significant, patients receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of 10 days or less (hazard ratio 1·52 [0·95-2·43]). Adverse events were reported in 102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients. Remdesivir was stopped early because of adverse events in 18 (12%) patients versus four (5%) patients who stopped placebo early.
INTERPRETATION: In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits. However, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies.
FUNDING: Chinese Academy of Medical Sciences Emergency Project of COVID-19, National Key Research and Development Program of China, the Beijing Science and Technology Project.
| Errataetall: |
CommentIn: Lancet. 2020 May 16;395(10236):1525-1527. - PMID 32423580 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:395 |
|---|---|
| Enthalten in: |
Lancet (London, England) - 395(2020), 10236 vom: 16. Mai, Seite 1569-1578 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Yeming [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3QKI37EEHE |
|---|
| Anmerkungen: |
Date Completed 29.05.2020 Date Revised 18.01.2023 published: Print-Electronic ClinicalTrials.gov: NCT04257656 CommentIn: Lancet. 2020 May 16;395(10236):1525-1527. - PMID 32423580 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S0140-6736(20)31022-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310061849 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310061849 | ||
| 003 | DE-627 | ||
| 005 | 20231225135257.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0140-6736(20)31022-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1033.xml |
| 035 | |a (DE-627)NLM310061849 | ||
| 035 | |a (NLM)32423584 | ||
| 035 | |a (PII)S0140-6736(20)31022-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Yeming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Remdesivir in adults with severe COVID-19 |b a randomised, double-blind, placebo-controlled, multicentre trial |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.05.2020 | ||
| 500 | |a Date Revised 18.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04257656 | ||
| 500 | |a CommentIn: Lancet. 2020 May 16;395(10236):1525-1527. - PMID 32423580 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models | ||
| 520 | |a METHODS: We did a randomised, double-blind, placebo-controlled, multicentre trial at ten hospitals in Hubei, China. Eligible patients were adults (aged ≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection, with an interval from symptom onset to enrolment of 12 days or less, oxygen saturation of 94% or less on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or less, and radiologically confirmed pneumonia. Patients were randomly assigned in a 2:1 ratio to intravenous remdesivir (200 mg on day 1 followed by 100 mg on days 2-10 in single daily infusions) or the same volume of placebo infusions for 10 days. Patients were permitted concomitant use of lopinavir-ritonavir, interferons, and corticosteroids. The primary endpoint was time to clinical improvement up to day 28, defined as the time (in days) from randomisation to the point of a decline of two levels on a six-point ordinal scale of clinical status (from 1=discharged to 6=death) or discharged alive from hospital, whichever came first. Primary analysis was done in the intention-to-treat (ITT) population and safety analysis was done in all patients who started their assigned treatment. This trial is registered with ClinicalTrials.gov, NCT04257656 | ||
| 520 | |a FINDINGS: Between Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to remdesivir and 79 to placebo); one patient in the placebo group who withdrew after randomisation was not included in the ITT population. Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1·23 [95% CI 0·87-1·75]). Although not statistically significant, patients receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of 10 days or less (hazard ratio 1·52 [0·95-2·43]). Adverse events were reported in 102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients. Remdesivir was stopped early because of adverse events in 18 (12%) patients versus four (5%) patients who stopped placebo early | ||
| 520 | |a INTERPRETATION: In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits. However, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies | ||
| 520 | |a FUNDING: Chinese Academy of Medical Sciences Emergency Project of COVID-19, National Key Research and Development Program of China, the Beijing Science and Technology Project | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a remdesivir |2 NLM | |
| 650 | 7 | |a 3QKI37EEHE |2 NLM | |
| 650 | 7 | |a Adenosine Monophosphate |2 NLM | |
| 650 | 7 | |a 415SHH325A |2 NLM | |
| 650 | 7 | |a Alanine |2 NLM | |
| 650 | 7 | |a OF5P57N2ZX |2 NLM | |
| 700 | 1 | |a Zhang, Dingyu |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Guanhua |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Ronghui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jianping |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Shouzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Zhenshun |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Qiaofa |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Guangwei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Huadong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shuzhen |e verfasserin |4 aut | |
| 700 | 1 | |a Ruan, Shunan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Chengqing |e verfasserin |4 aut | |
| 700 | 1 | |a Mei, Chunlin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Xianzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Yingchun |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Bing |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Aili |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Guohui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhibo |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Xiaoying |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Jiuyang |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, Lianhan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Lianjun |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Tingting |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Yushen |e verfasserin |4 aut | |
| 700 | 1 | |a Jaki, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Hayden, Frederick G |e verfasserin |4 aut | |
| 700 | 1 | |a Horby, Peter W |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lancet (London, England) |d 1945 |g 395(2020), 10236 vom: 16. Mai, Seite 1569-1578 |w (DE-627)NLM000473936 |x 1474-547X |7 nnns |
| 773 | 1 | 8 | |g volume:395 |g year:2020 |g number:10236 |g day:16 |g month:05 |g pages:1569-1578 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S0140-6736(20)31022-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 395 |j 2020 |e 10236 |b 16 |c 05 |h 1569-1578 | ||